102-D - Platform Research Part 4 of 4: Predictive Factors of Dose Reduction Among Patients Treated With Palbociclib

Session Description:The palbociclib monograph recommends a starting dose of 125 mg/day with subsequent dose reductions during treatment if adverse events occur. In practice, clinicians sometimes choose to initiate palbociclib at a lower dose to prevent adverse effects in patients deemed more likely to experience them. This retrospective study, conducted at the Centre Hospitalier de l’Université de Montréal (CHUM) in Quebec, Canada, aimed to identify baseline patient characteristics that may predict the need for palbociclib dose reduction during treatment. Secondary outcomes include treatment patterns, clinical outcomes and a description and frequency of pharmacist interventions during the study period. A total of 149 patients with advanced or metastatic breast cancer undergoing palbociclib treatment between April 2019 and June 2022 were included.